J (@jayabacus) header
J (@jayabacus) profile picture

There isn't a day that goes by that I don't think about the 3 L's from Charlie! Good luck boys!

FL, USA
Joined September 2012
Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)Photo by J (@jayabacus)
I lost my best bud yesterday, very sad days. Boots was an awesome addition to our family and gave us 9 incredible years. He will be missed forever 💔
21
1
104
12,224
It kills me, how does Jenson have all the fun slinging his dick around the office and we’re all paying the price? It’s ridiculous
1
6
1,239
Madden on Amazon is fantastic esp for us guys who were around back in the day.
1
3
933
They can’t get text recognition right after a decade. I don’t think anyone has to worry about $aapl $ant
*APPLE IS WORKING ON OWN AI AGENT TO RIVAL OPENAI AND ANTHROPIC ANTHROPIC SHARES JUST 4% AFTER HOURS DAY WHAT A DAY FOR APPLE TO LEAK THE STORY RIGHT AFTER THE IPO $AAPL $ANT
6
1,031
Elon Musk predicts Tesla's Optimus will be able to do household chores in 12 to 18 months, but says its first job will be heavy industry: “Picking up, say, a plate that’s still got food remnants on it… wiping the food off the plate, putting it under the sink, washing it, drying it, and then putting it safely back in the closet. There’s no humanoid robot that can do that at all.” “I think Optimus will be able to do it in 12 to 18 months.” “Optimus could be many things. It could be a teaching tutor for your kids. It could be a babysitter, watch over, protect your kids, make sure they’re okay, and teach them things. It could mow the lawn… cook dinner.” “Most people would love to have their own personal R2-D2, C-3PO, but that’s even more useful than that.” So what’s the highest and best use at first? “It would probably be heavy industry. So, like mining and refining ore.” “The United States has a very high degree of dependence on other countries for mining and refining ore. And I think we need to make sure for our national security that we can do so within the country.” “Once you get through those 24/7, kind of heavy industry jobs, at some point it’ll make sense for people to have one in their home. And I think pretty much everyone’s going to want one, if not two.”
140
367
26
2,864
185,660
$MDT - NEEDHAM basically calling out $MDT you need $AVR more then ever to compete ??🤷‍♂️ note that MDT has seen some pressure on its transcatheter aortic valve replacement (TAVR) business due to 6-7 year data from the Evolut Low Risk trial that showed a higher reintervention rate compared to surgery (5.5% vs. 3.3% at 6 years) which was driven by aortic regurgitation. Management noted that while this hurt US TAVR growth initially, they have seen procedure volumes stabilize. On our recent cardiology expert call, Dr. Andrew Goldsweig indicated that the market increasingly favors balloon-expandable TAVR designs and that Edwards Lifesciences' (EW - Not Covered) currently has the best TAVR and that MDT is at risk of market share loss until it launches its own balloon-expandable TAVR.
5
4
1
17
7,731
💯
Lately, I’ve seen a growing number of SpaceX investor accounts on X, and even some longtime Tesla accounts, trying to rationalize why Tesla is overvalued and why SpaceX shouldn’t have to pay a significant premium to acquire it. Even Gali @Gfilche pointed out that Tesla’s current valuation already prices in some degree of robotaxi success, to which @elonmusk replied, “Of course.” And by the way, I agree with that assessment. But some $SpaceX investors have gone much further, calling Tesla shareholders greedy, suggesting ridiculously low acquisition prices, and one even arguing that only a 1:1 share exchange ratio makes sense. So I feel compelled to point out something incredibly obvious that many of them seem determined to ignore. I can only speak for myself, but I suspect many longtime Tesla shareholders feel the same way. Arguing about what constitutes a “fair” valuation is a waste of time. Everyone has their own interests, and everyone will naturally argue for the outcome that benefits them the most. What actually matters is how badly SpaceX and Tesla shareholders want this merger. And when I say SpaceX shareholders, I really mean Elon, because his voting control is what ultimately matters on the SpaceX side. On Tesla’s side, however, it’s a completely different story. Getting the necessary shareholder approval will be extremely difficult, especially considering that institutions now hold the majority of Tesla shares, while retail investors account for a much smaller percentage. And here is what many SpaceX investors seem to be missing. Longtime Tesla shareholders have endured YEARS!!! of extreme volatility, missed deadlines, constantly changing goals, unfulfilled promises, and endless criticism, because they believed in FSD, robotaxis, and Optimus. They believed Elon could eventually deliver on goals that most people considered impossible. They patiently held their shares while Tesla invested billions developing technologies that much of WS dismissed as fantasies. And now, just as Tesla is finally on the cusp of reaping the rewards of those years of investment, you expect those shareholders to hand over their company without a substantial premium? Are you out of your damn mind? Why would they? Tesla shareholders have already waited this long. Many would gladly wait a few more years to see robotaxis scale, Optimus enter mass production, and the enormous potential of those businesses reflected in Tesla’s valuation. They know the long term advantage of this merger for both shareholders, but they don’t need this merger to get good returns. And that’s the fundamental point so many SpaceX investors are ignoring. SpaceX doesn’t get to decide what Tesla is worth to its shareholders. Tesla shareholders get to decide what price makes them willing to sell. You can argue all day that Tesla is overvalued, that its stock already prices in future success, or that SpaceX deserves a better deal. None of that changes the reality that you need Tesla shareholders to approve the transaction. And I don’t see a snowball’s chance in hell of getting that approval without offering a substantial premium that makes giving up Tesla’s independent future worthwhile. I’m a SpaceX shareholder myself, and I would love to see these two companies merge. I believe the combination could create enormous value. But wanting a merger doesn’t mean I’m willing to give away my Tesla shares at a discount to what I believe their future is worth. So to my fellow SpaceX investors who genuinely want this merger, I have a very simple message, get ready to accept some dilution, because if you want to acquire Tesla, you have to convince its shareholders to sell. #Tesla #SpaceX
3
1,010
💯
$CEPL headline numbers were a miss, but the outlook has massively improved. For the first time, management gave detailed sales pipeline information (page 12 of the earnings presentation). An edge compute deal is highly likely to be signed in the next month or two, according to this slide and Vince’s voiceover during the call. Assuming 20mw and $2mm/mw pricing, this single agreement alone will bump revenues by 40% for FY27. There is a lot of noise around margins given the high share of oil and gas rentals in Capstone’s revenue mix. I would expect margins on this potential $40mm deal to be around the 30% number the company realized for equipment sales and rentals last quarter (it isn’t clear to me whether the edge developer is buying energy as a service or turbines outright, but margins should be in that ballpark in either case). This would add around $10-12mm of ebitda to FY27. The key part is that this is only one deal. Between the rest of the DC pipeline (another 2.45GW), ports (110 mw), and grid resilience (239m mw), the company has a line of site to nearly $6 billion of new revenue. Haircut that by 60% and it is still massive when compared to the $100-125mm of revenues the company has been realizing in recent years. The quality of this revenue is much better as well. O&G rentals are unstable due to commodity pricing and geopolitics. On the other hand, data centers and grid resiliency will not get turned off and on every quarter. The stability of these revenues (remember that these larger deployments will also come with high margin service agreements) may also help rerate the stock higher. I believe that $CEPL will be off to the races once the first >20mw deal is signed. The evidence points towards this happening in the next month or two. It has been a longer than expected road to get there, but I think the inflection point is in sight and I look forward to being along for the ride.
2
801
Fully diluted mkt cap of $cepl is $150m today with $25m in cash and $25m in debt. They just reported a rough qtr, but was able to refi debt and it seems like they are close to being back on track or above. Slide 12 of last night’s release shows they’re discussing $5b in data center orders, $200m in port orders and micro grid discussion, and they have a deposit for at least one data center order. Incredible activity for a current run rate of $100m. Lots of upside if they can land even 5% of them, maybe 3-5x on this. But what if it’s real, and the demand from the edge drives sales beyond 5%? Now we could be talking about up to 50x. And why not, it’s the biggest bottleneck out there, and they have a viable solution. Turbines are the rage and I don’t see the power gap closing anytime soon. The history of $cepl isn’t clean but that’s probably true for 95% of the small/medium caps trading? I think their time is coming, if not with the current team, Monarch has full control here and will bring in more heavy hitters like they did last week. Brandon the new BOD member built an energy related company from $7m to $100m EBITDA, he’s the man and more like him will come, maybe for the ceo position as well. It’s all a risk of course but given what’s happening in their sales pipeline, tiny mkt cap, and product portfolio, I’ll take this risk everyday win or lose. Long $cepl
1
10
1,287
Amidst all the chaos that happened in the past few days, this makes me feel proud of humanity.
After careful consideration I’ve decided I’m quite bullish on civilization KARDASHEV II HERE WE COME!
96
228
6
3,046
451,561
2015. Bernie Sanders: Open borders is a right wing proposal to bring in cheap labor. Immigration makes Americans poorer. Bernie says the complete opposite today. What a fraud.
1,127
12,958
1,059
49,257
1,427,202
$NKTR OPPY PT $140 Off-treatment AD data in 1Q27 could further differentiate rezpeg’s durability. NKTR plans to assess clinical responses through 52-weeks after treatment cessation, following one full year of therapy. Mgt highlighted ~50% EASI-75 retention at 12-months as potentially differentiated vs. dupilumab’s nine- month withdrawal data. believe sustained responses could support quarterly maintenance, with 6-month dosing potentially appropriate for deep responders, pending further clinical evaluation.
My outlook on $NKTR. Still own shares - disappointing performance in 2H26 no doubt, though nothing really changed fundamentally in that time period either. The AA update was an incremental and hard to interpret dataset that was treated realistically more like a liquidity event. Similarly, the AtD off-treatment update in 1H27 is unlikely to be anything seismic. Maybe a bit more informative than AA off treatment data, but I don't think it's going to make or break anyone's thesis. The setup from here is pretty simple...Viable drug with unique MoA in 1 HUGE market and 1 mid size market that has very weak competition. Dual indication derm launch with a unique MoA in a safe biologic with Q3M dosing? There's value there. Now, of course, we have to see that safety stays on track through all these P3 studies. There doesn't seem to be any whiff of safety concern so far, so that's encouraging, but they run these studies for a reason - you never know! We ultimately have to see safety hold up for this to work long term. Efficacy so far looks worse than IL4/13, obviously, which some people really get hung up on. Such a myopic view is hard for me to grasp, because the pitch here has *long* (always?) been use in patients for whom dupi/lebri/adbry/$APGE/$KYMR drugs don't work...which is about half of atopic derm patients...And yes, those drugs are *all* on the exact same mechanistic axis. There's really only one drug on the market today that ISN'T on that axis...Nemluvio. Its efficacy is terrible, yet it is going to be a multi-blockbuster drug. Rezpeg so far is showing much better efficacy, much sparser dosing, and potential to enter a secondary indication that is much larger than nemluvio's and where it will compete only with JAK inhibitors...not with the king dupixent like Nemluvio has to battle in PN. "It's worse than dupi" is an unbelievably stupid and uninformed bear thesis, but I have heard it regularly for 2 years straight...whatever. Everybody seemed to understand the *differentiated MoA* argument for OX40 drugs when $AMGN and $SNY were saying these things were gonna generate tens of billions of dollars in revenue...not sure why it is so hard to understand now for Rezpeg? Not sure why its so universal to completely ignore Nemluvio's success as a *vastly* inferior drug with an alternative MoA? 🤷‍♂️ Down the road more competition will emerge, likely including bispecifics that hopefully bring us something other than IL4/13/STAT6. Still, Rezpeg is well on its way to be *years* ahead of them in getting to market. Getting entrenched as a drug with a safe, effective, unique MoA drug with a Q3M dosing interval...to me that looks like an eventuality *if* the P3 data hold up similar to P2. Another note - $NKTR is currently the ONLY company running a biologic refractory phase 3 in atopic derm. That hitting would be a MASSIVE advantage for them in competitng with other drugs, being the *only* option labeled for use in patients who have failed other biologics...which, given the size of and response rates in AtD, would still potentially be one of the top 5 biggest opportunity in all of I&I...The market opportunity here is just absurdly big. AA P3 will, in my opinion, hit, making Rezpeg the first and only safe biologic approved for that disease. The JAK inhibitors see little use there because it is a borderline cosmetic condition of hair loss...many providers and patients are not willing to take the (potentially fatal) labeled risks that come on the JAK inhibitors' black box warning. Again we here the uninformed "but it is less effective than the JAKs" argument from the bears. This argument couldn't possibly be more debunkable...look at Atopic dermatitis as your exemplar - the JAK inhibitors are nearly 2x more effective than the IL4/13 inhibitors, yet the 4/13 inhibitors get used 10x more than the JAKs...DERMATOLOGISTS CHOOSE THE SAFEST DRUG FIRST, PERIOD. The same WILL be the case in alopecia areata, meaning that if Rezpeg succeeds there, it will dominate the AA market until another safe biologic comes along that's better. And I wouldn't hold my breath waiting for that given the many failures (including dupixent) that we have seen in that space. Anyway, I'm not "pounding the table" here by any means. But, $NKTR trading near cash at this stage still feels like very solid risk/reward skew. If the P3 trials reproduce near the efficacy they showed in P2 and the drug remains safe in these larger/longer datasets, they've got a window to have blockbuster launches in 2 derm indications at once. That's pretty rare, and I can't imagine it wouldn't attract significant pharma/investor interest. Risks remain OBVIOUSLY. There is no guarantee of a happy ending to any story where 4 P3 trials still await results. But when you're paying just a little more than cash on hand for a drug with a unique MoA, sparse dosing, and a record of meaningful efficacy and safety in 2 large TAMs (including AtD, *the* largest TAM in all of I&I)...that seems like a decent deal to me, even if the market is going to treat it like "dead money" for a while.
2
1
42
6,209
38% of TAVR pts left with PPM. Severe PPM pts felt as good as everyone at 1 yr, then by 3 yrs only 31% were alive & well vs 49%. The damage shows up late, and the younger the patient, the more years it has to show up. $AVR DurAVR: 0% severe PPM in small and medium annuli so far.
🫀New in #JACCINT: Severe prosthesis–patient mismatch (PPM) after #TAVR was linked to worse 3-year health status! 📉 Only 30.6% achieved good health vs 49.4% without PPM. ⚠️ Residual MR may contribute. 🩺 Patient-centered outcomes matter! ❤️🏥📊 bit.ly/4kPuqVC #vhdMR
2
1
11
1,506
$NKTR BRiley BUY PT $150 3Q results were ahead of Street on lower R&D, YE26 cash guidance moved above $840M with runway into 3Q28. •1Q27 off-treatment AtD readout is only efficacy dataset in the next 12 months, and expect roughly half to 60% of responders to hold EASI-75 a year after stopping Rezpeg, supporting quarterly dosing. ZENITH-AD remains on track for summer 2028 topline, ZENITH-AA now starts in December vs. early 2027, and a vitiligo PoC study adds a second JAK-only market. EV has compressed to ~$0.3B against $953M in cash, heavily discounting ~$2B 2034 risk-adjusted revenue forecast.
$NKTR ZENITH-AD 2. Based on regulatory feedback, ZENITH-AD 2 (previously planned as a 2nd monotherapy trial in biologic/JAKi naive pts) will now include background TCS & enroll both biologic/JAKi naive and experienced participants. All three ZENITH-AD trials — ZENITH-AD 1 (monotx, naive), 2 (in combination with TCS), a 3 (biologic/JAKi experienced) have now been initiated
1
5
31
4,835
Can’t wait! Hopefully you’ll have something exciting to talk about regarding excellent refi terms and new contracts!
Capstone Energy+ Reschedules Second Quarter Fiscal Year 2027 Earnings Conference Call and Webcast to Monday, November 16, 2026 at 4:45 p.m. ET
1
4
1,011
Adam Destroys Gavin Newsom !
53
1,255
19
7,326
336,152
Man, we need ai to start showing productivity gains stat!
4
763
Replying to @semodough
Cowen's own $EW bull note: AS should be judged by "myocardial damage and functional impairment," not just the valve. Moderate AS could grow TAVR 1.5×. Agreed. LANDMARK: damage drives mortality. Garg MRI: DurAVR normalizes flow, and flow predicts LV regression. $AVR 🤷‍♂️
1
1
5
727
NOW WE KNOW WHY FLORIDA ISN'T GOING BLUE: Florida passed its own version of the SAVE Act earlier this year. It requires citizenship verification using REAL ID data for voter registrations and mandates paper ballots. The measure also requires federal candidates to disclose stock trading while in office and sets a five year statute of limitations for felony election offenses. The bill cleared both chambers with Republican majorities before being signed in April.
119
890
31
3,637
158,668
Can you imagine if Musk didn’t buy X. There would be nothing but Liberal propaganda everywhere. Thanks Elon for saving free speech
329
1,661
53
23,006
197,112